Royce & Associates LP Has $1.01 Million Holdings in Cytek Biosciences, Inc. (NASDAQ:CTKB)

Royce & Associates LP raised its position in Cytek Biosciences, Inc. (NASDAQ:CTKB) by 51.8% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 181,394 shares of the company’s stock after purchasing an additional 61,916 shares during the period. Royce & Associates LP’s holdings in Cytek Biosciences were worth $1,005,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the company. ProShare Advisors LLC raised its position in Cytek Biosciences by 7.6% in the 1st quarter. ProShare Advisors LLC now owns 23,941 shares of the company’s stock valued at $161,000 after buying an additional 1,687 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Cytek Biosciences by 1.0% in the first quarter. Vanguard Group Inc. now owns 12,012,805 shares of the company’s stock valued at $80,606,000 after purchasing an additional 122,105 shares during the last quarter. Quadrature Capital Ltd bought a new stake in shares of Cytek Biosciences in the first quarter worth $102,000. Price T Rowe Associates Inc. MD boosted its holdings in Cytek Biosciences by 13.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 34,665 shares of the company’s stock worth $233,000 after purchasing an additional 3,987 shares during the last quarter. Finally, SG Americas Securities LLC bought a new position in Cytek Biosciences in the second quarter valued at $180,000. 69.46% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Piper Sandler increased their price objective on shares of Cytek Biosciences from $8.00 to $8.50 and gave the stock an “overweight” rating in a research note on Monday, November 11th.

Cytek Biosciences Price Performance

Shares of Cytek Biosciences stock opened at $6.13 on Thursday. The stock has a market cap of $789.61 million, a P/E ratio of -76.63 and a beta of 1.32. Cytek Biosciences, Inc. has a 12-month low of $4.66 and a 12-month high of $9.87. The business’s 50 day moving average is $5.45 and its 200-day moving average is $5.70.

Cytek Biosciences (NASDAQ:CTKB) last posted its quarterly earnings results on Tuesday, November 5th. The company reported $0.01 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.02) by $0.03. Cytek Biosciences had a negative net margin of 5.05% and a negative return on equity of 2.58%. The firm had revenue of $51.50 million for the quarter, compared to analyst estimates of $50.63 million. During the same period in the prior year, the firm posted ($0.03) earnings per share. On average, sell-side analysts expect that Cytek Biosciences, Inc. will post -0.07 EPS for the current year.

Cytek Biosciences Company Profile

Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems.